PhRMA member companies invested $83 billion in research and development last year
By Tim McClung | September 10, 2020
PhRMA member companies invested $83 billion in research and development (R&D) in 2019, the highest level of investment on record, according to the 2020 PhRMA member annual survey. Over the past...
Read More
Coming together to fight COVID-19: A conversation with Joaquin Duato, vice chairman of the executive committee at Johnson & Johnson
By Stephen J. Ubl | September 9, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent...
Read More
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
By Stephen J. Ubl | September 2, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent...
Read More
Three ways the pharmaceutical industry can positively impact health equity
By Guest Contributor | September 1, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
By Andrew Powaleny | August 4, 2020
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...
Read More
New report explores setbacks that bring future cancer success stories
By Giovanni Caforio, M.D. | July 16, 2020
Conversations and healthy debate about issues facing the biopharmaceutical industry and the health care system are critical to addressing the important work we do for patients. The Catalyst...
Read More
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
By Guest Contributor | June 24, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
In combating COVID-19, science is how we get back to normal
By Lori Reilly | June 24, 2020
America’s biopharmaceutical companies are working around the clock to combat a common enemy: COVID-19. As the fight to research and develop innovative treatments and vaccines advances, I’m pleased...
Read More
Guest Post: What will we learn from COVID-19?
By Guest Contributor | May 27, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
By Stephen J. Ubl | April 15, 2020
As biopharmaceutical companies continue to fight COVID-19 through research and development, three companies have created programs empowering employees with medical or laboratory expertise to...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
